

# UCSF

## UC San Francisco Previously Published Works

### Title

Corrigendum: CRISPR nuclease off-target activity and mitigation strategies

### Permalink

<https://escholarship.org/uc/item/30p1p10c>

### Authors

Wienert, Beeke

Cromer, M Kyle

### Publication Date

2022

### DOI

10.3389/fgeed.2022.1112956

### Copyright Information

This work is made available under the terms of a Creative Commons Attribution-NoDerivatives License, available at <https://creativecommons.org/licenses/by-nd/4.0/>

Peer reviewed



## OPEN ACCESS

EDITED AND REVIEWED BY  
Ayal Hendel,  
Bar-Ilan University, Israel

\*CORRESPONDENCE  
M. Kyle Cromer,  
✉ kyle.cromer@ucsf.edu

SPECIALTY SECTION  
This article was submitted to Genome  
Editing in Blood Disorders,  
a section of the journal  
Frontiers in Genome Editing

RECEIVED 30 November 2022  
ACCEPTED 02 December 2022  
PUBLISHED 20 January 2023

CITATION  
Wienert B and Cromer MK (2023),  
Corrigendum: CRISPR nuclease off-  
target activity and mitigation strategies.  
*Front. Genome Ed.* 4:1112956.  
doi: 10.3389/fgeed.2022.1112956

COPYRIGHT  
© 2023 Wienert and Cromer. This is an  
open-access article distributed under  
the terms of the [Creative Commons  
Attribution License \(CC BY\)](#). The use,  
distribution or reproduction in other  
forums is permitted, provided the  
original author(s) and the copyright  
owner(s) are credited and that the  
original publication in this journal is  
cited, in accordance with accepted  
academic practice. No use, distribution  
or reproduction is permitted which does  
not comply with these terms.

# Corrigendum: CRISPR nuclease off-target activity and mitigation strategies

Beeke Wienert<sup>1</sup> and M. Kyle Cromer<sup>2,3,4\*</sup>

<sup>1</sup>Graphite Bio, Inc., South San Francisco, CA, United States, <sup>2</sup>Department of Surgery, University of California, San Francisco, San Francisco, CA, United States, <sup>3</sup>Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA, United States, <sup>4</sup>Eli and Edythe Broad Center for Regeneration Medicine, University of California, San Francisco, San Francisco, CA, United States

## KEYWORDS

gene therapy, off-target activity, *in vivo* delivery, genome editing, CRISPR/Cas9, next-generating sequencing

## A Corrigendum on CRISPR nuclease off-target activity and mitigation strategies

by Wienert B and Cromer MK (2022). *Front. Genome Ed.* 4:1050507. doi: 10.3389/fgeed.2022.1050507

In the published article, “Dobbs et al., 2022” was cited incorrectly in the article. The citation has now been inserted at the correct location in the section, “**Methods to find off-targets sites in genome editing applications**”, paragraph three, and should read: “These methods vary widely in their approach and even starting material, using cell-free genomic DNA *in vitro* (Kim et al., 2015; Cameron et al., 2017; Tsai et al., 2017; Kim and Kim, 2018; Lazzarotto et al., 2020), in intact live cells *ex vivo* (Crosetto et al., 2013; Tsai et al., 2015; Yan et al., 2017; Wienert et al., 2019; 2020; Zhu et al., 2019; Dobbs et al., 2022), and *in vivo* animal models (Akcakaya et al., 2018; Wienert et al., 2019; Liang et al., 2022).”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.